DiaCura - Praxis für Radiologische Diagnostik, Strahlentherapie und Radioonkologie

Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial (2021) Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, et al. Journal article TNT in rectal cancer: Final results of the CAO/ARO/AIO-12 randomized phase 2 trial (2021) Fokas E, Schlenska-Lange A, Polat B, Klautke G, Fietkau R, Kuhnt T, Brunner T, et al. Conference contribution Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Final results of the CAO/ARO/AIO-12 randomized phase 2 trial (2021) Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer G, Fietkau R, Kuhnt T, et al. Conference contribution Left breast irradiation with tangential intensity modulated radiotherapy (t-IMRT) versus tangential volumetric modulated arc therapy (t-VMAT): Trade-offs between secondary cancer induction risk and optimal target coverage (2019) Karpf D, Sakka M, Metzger M, Grabenbauer GG Journal article Randomized phase 2 trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12 (2019) Hofheinz R, Fokas E, Allgaeuer M, Polat B, Klautke G, Grabenbauer G, Fietkau R, et al. Conference contribution Chemoradiotherapy plus induction versus consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-12 multicentre, open-label, randomised, phase 2 trial (2019) Fokas E, Allgaeuer M, Polat B, Klautke G, Grabenbauer G, Fietkau R, Kuhnt T, et al. Conference contribution Chemo-RT plus induction or consolidation chemotherapy for rectal cancer: a randomised phase 2 trial (2019) Fokas E, Allgaeuer M, Polat B, Klautke G, Grabenbauer G, Fietkau R, Kuhnt T, et al. Conference contribution QoL after multimodal treatment of rectal cancer with/without oxaliplatin (phase 3, CAO/ARO/AIO-04) (2019) Kosmala R, Fokas E, Flentje M, Sauer R, Liersch T, Graeven U, Fietkau R, et al. Conference contribution Neutrophilia as prognostic factor for outcome in the CAO/ARO/ALO-04 phase 3 rectal cancer trial (2019) Diefenhardt M, Hofheinz R, Beissbarth T, Arnold D, Von Den Gruen JM, Liersch T, Stroebel P, et al. Conference contribution NAR score as surrogate for disease-free survival in the CAO/ARO/AIO-04 phase 3 rectal cancer trial (2018) Fokas E, Fietkau R, Hartmann A, Hohenberger W, Grützmann R, Ghadimi M, Liersch T, et al. Conference contribution